Skip to main content
GeoVax Labs, Inc. logo

GeoVax Labs, Inc. — Investor Relations & Filings

Ticker · GOVX ISIN · US3736786068 LEI · 549300KXK8Z4UZ4J7S86 US Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country US United States of America
Listing US GOVX

About GeoVax Labs, Inc.

https://www.geovax.com/

GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms. The company's lead oncology program is Gedeptin®, a therapy for advanced head and neck cancers which has completed enrollment in a Phase 1/2 clinical trial. Its primary infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine being evaluated in Phase 2 clinical trials for high-risk, immunocompromised populations and as a heterologous booster. GeoVax's development pipeline also includes research programs for preventive vaccines against Mpox, smallpox, hemorrhagic fever viruses such as Ebola and Marburg, malaria, and Zika virus, alongside therapies for various solid tumors.

Recent filings

Filing Released Lang Actions
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
Regulatory Filings Classification · 1% confidence The document is a corporate press release detailing clinical development milestones and strategic partnership opportunities for GeoVax’s oncology program. It does not contain financial statements or detailed quantitative results, nor is it an earnings release, annual or quarterly report, or proxy solicitation. It is a general regulatory announcement/press release and does not fit any more specific category, so it is classified as a Regulatory Filing (RNS).
2026-04-29 English
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
Regulatory Filings Classification · 1% confidence The document is a corporate news press release from GeoVax highlighting its oncology asset Gedeptin® and providing background on the product, industry context, and forward-looking statements. It does not contain financial results (no earnings data) or specific regulatory form attachments, nor does it announce dividends, board changes, share issues, M&A, or similar events. Instead, it is a general corporate announcement disseminated via EQS News, fitting the fallback category for miscellaneous regulatory/corporate announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-27 English
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
Regulatory Filings
2026-04-15 English
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
Earnings Release Classification · 1% confidence The document is a corporate press release announcing GeoVax’s 2025 full-year financial results with key operational highlights and summary financial tables. It is not the full Form 10-K filing itself but an initial earnings announcement covering year-end performance. Therefore, it falls under the Earnings Release category. FY 2025
2026-04-15 English
10-K - GeoVax Labs, Inc. (0000832489) (Filer)
Annual Report FY 2025
2026-04-15 English
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
Regulatory Filings Classification · 1% confidence The document is a corporate press release distributed via EQS News Service, discussing GeoVax’s strategic positioning of its GEO-MVA vaccine candidate in the mpox/smallpox market. It does not present financial results, regulatory reports, capital transactions, board changes, dividends, or other specific filing content. It is a general corporate announcement and thus falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.